Influence of humoral and neurohormonal factors on cardiovascular hypertrophy in untreated essential hypertensives

American Journal of Hypertension

Volumn 9, Issue 3, 1996, Pages 207-215

  Schroeder, Anne Pauline ^b,d   Sihm, Inger ^a   Mørn, Birgitte ^a   Thygesen, Kristian ^a   Pedersen, Erling Bjerregaard ^c   Lederballe, Ole ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b VIBORG HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d NONE   (Denmark)

Author keywords

Essential hypertension; Hormonal factors; Left ventricular hypertrophy; Resistance vessel structure

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; CATECHOLAMINE;

ADULT; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEART VENTRICLE SEPTUM; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL;

EID: 0029880011     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(95)00352-5     Document Type: Article

References (36)

1. Dzau VJ, Gibbons GH: Endothelium and growth factors in vascular remodeling of hypertension. Hypertension 1991;18(suppl III):III-115-III-121.
2. Heagerty AM: Angiotensin II: Vasoconstrictor or growth factor? J Cardiovasc Pharm 1991;18(suppl 2):s14-s19.
3. Dzau VJ: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988;77(suppl I):I-4-I-13.
4. Laragh JH: Role of renin secretion and kidney function in hypertension and attendant heart attack and stroke. Clin Exp Hypertens [A] 1992;A14(1&2):285-305.
5. Berk BC, Vekshtein V, Gordon HM, Tsuda T: Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989;13:305-314.
6. Campbell-Boswell M, Robertson AL: Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol 1981;35:265-276.
7. Golomb E, Abassi ZA, Cuda G, et al: Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. Am J Physiol 1994;267:H1496-H1506.
8. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865.
9. Musca A, Cammarella I, Ferri C, et al. Natriuretic hormones in young hypertensives and in young normotensives with or without a family history of hypertension. Am J Hypertens 1992;5:592-599.
10. Dessì-Fulgheri P, Palermo R, Di Noto G, et al: High levels of plasma natriuretic factor and impaired left ventricular diastolic function in hypertensives without left ventricular hypertrophy. J Hypertens 1992;10:161-165.
11. Genest J, Larochelle P, Cusson JR, Gutkowska J, Cantin M: The atrial natriuretic factor in hypertension. Hypertension 1988;11(suppl I):I-3-I-7.
12. Rossi MA, Carillo SV: Does norepinephrine play a central causative role in the process of cardiac hypertrophy? Am Heart J 1985;109:622-624.
13. Pfeffer MA, Lamas GA, Vaughan DE, et al: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988; 319:80-86.
14. Mann DL, Kent RL, Parsons B, Cooper G, IV: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
15. Shub C, Cueta-Garcia L, Sheps SG, et al: Echocardiographic findings in pheochromocytoma. Am J Cardiol 1986;57:971-975.
16. Fouad-Tarazi FM, Imamura M, Bravo EL, et al: Differences in left ventricular structural and functional changes between pheochromocytoma and essential hypertension. Role of elevated circulating catecholamines. Am J Hypertens 1992;5:134-140.
17. Kappelgaard AM, Nielsen MD, Giese J: Measurement of angiotensin II in human plasma: technical modifications and practical experience. Clin Chem Acta 1976;67:299-306.
18. Rask-Madsen J, Bruunsgaard A, Munck O, et al: The significance of bile acids and aldosterone for the electrical hyperpolarization of human rectum in obese patients with intestinal by-pass operation. Scand J Gastroenterol 1974; 9:417-426.
19. Thomassen AR, Bagger JP, Nielsen TT, Pedersen EB: Atrial natriuretic peptide during pacing in controls and patients with coronary arterial disease. Int J Cardiol 1987;17:267-276.
20. Davidson DF, Fitzpatrick J: A simple, optimised and rapid assay for urinary free catecholamines by HPLC with electrochemical detection. Ann Clin Biochem 1985;22:297-303.
21. Vendsalu A: Studies on adrenaline and noradrenaline in human plasma. Acta Physiol Scand 1960;49(suppl 173):23-32.
22. White WB, Pickering TG, Morganroth J, et al: A multicenter evaluation of the A&D TM-2420 ambulatory blood pressure recorder. Am J Hypertens 1991;4:890-896.
23. Clark S, Fowlie S, Coats A, et al: Ambulatory blood pressure monitoring: validation of the accuracy and reliability of the TM-2420 according to the AAMI recommendations. J Human Hypertens 1991;5:77-82.
24. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-618.
25. Devereux RB, Pickering TG, Alderman MH, et al: Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. Hypertension 1987;9(suppl II):II53-II60.
26. Heagerty AM, Bund SJ, Aalkjær C: Effects of drug treatment on human resistance arteriole morphology in essential hypertension: Direct evidence for structural remodel ling of resistance vessels. Lancet 1988;1209-1212.
27. Sihm I, Schroeder AP, Aalkjær C, et al: The relation between peripheral vascular structure, left ventricular hypertrophy, and ambulatory blood pressure in essential hypertension. Am J Hypertens 1995;8:987-995.
28. Sugishita Y, Iida K, Yukisada K, Ito I: Cardiac determinants of regression of left ventricular hypertrophy in essential hypertension with antihypertensive treatment. J Am Coll Cardiol 1990;15:665-671.
29. Corea L, Bentivoglio M, Verdecchia P, Motolese M: Plasma norepinephrine and left ventricular hypertrophy in systemic hypertension. Am J Cardiol 1984; 53:1299-1303.
30. Bauwens FR, Duprez DA, DeBuyzere ML, et al: Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1992;68:925-929.
31. Schmieder RE, Messerli FH, Garavaglia GE, et al: Does the renin-angiotensin-aldosterone systerm modify cardiac structure and function in essential hypertension? Am J Med 1988;84(suppl 3A):136-139.
32. Franco-Saenz R, Somani P, Mulrow PJ: Effect of atrial natriuretic peptide (8-33-Met ANP) in patients with hypertension. Am J Hypertens 1992;5:266-275.
33. Ekholm D, Edvinsson L, Ekman T, Thulin T: Plasma atrial natriuretic peptide (ANP) in relation to blood pressure in severe hypertension. J Intern Med 1992;231:281-285.
34. Doyle AE: Role of angiotensin-converting enzyme inhibitors in preventing or reducing end-organ damage in hypertension. J Cardiovasc Pharm 1992;19(suppl 5):s21-s27.
35. Sivertsson R: The hemodynamic importance of structural vascular changes in essential hypertension. Acta Physiol Scand 1970;suppl 343:1-56.
36. Aalkjær C, Eiskjær H, Mulvany MJ, et al. Abnormal structure and function of isolated subcutaneous resistance vessels from essential hypertensive patients despite antihypertensive treatment. J Hypertension 1989; 7:305-310.